2. Academic Validation
  3. Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform

  • J Med Chem. 2024 Dec 26;67(24):21811-21840. doi: 10.1021/acs.jmedchem.4c01405.
Hideyuki Igawa 1,  Zef A Konst 1,  Eric Therrien 1,  Mee Shelley 2,  Heidi Koldsø 1,  Pieter H Bos 1,  Ana Negri 1,  Andreas Verras 1,  Jiaye Guo 1,  Markus K Dahlgren 1,  Adam Levinson 1,  Brendan T Parr 2,  Suresh E Kurhade 3,  Prashant Latthe 4,  Rajesha Shetty 4,  Sridhar Santhanakrishnan 4,  Katherine Amberg-Johnson 1,  Alan S Futran 1,  Christian Atsriku 1,  Robert D Pelletier 1,  Zhijian Liu 1,  Jeffrey A Bell 1,  Sathesh Bhat 1,  Mats Svensson 1,  Aleksey I Gerasyuto 1
Affiliations

Affiliations

  • 1 Schrödinger Inc., New York, New York 10036, United States.
  • 2 Schrödinger Inc., Portland, Oregon 97204, United States.
  • 3 Schrödinger Inc., Hyderabad, Telangana 50081, India.
  • 4 Syngene International Ltd., Bengaluru, Karnataka 560099, India.
PMID: 39666597 DOI: 10.1021/acs.jmedchem.4c01405
Abstract

Despite the success of first, second, and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung Cancer with classical EGFR mutations (L858R or Exon 19 deletions), disease progression occurs due to the acquisition of T790M and C797S resistance. Herein, we report a physics-based computationally driven lead identification approach that identified structurally unique imidazo[3.2-b]pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations bearing both T790M and C797S. During profiling of imidazo[3.2-b]pyrazoles, we elucidated the bioactivation mechanism causing CYP3A4/5 time-dependent inhibition (TDI) and found key modifications to mitigate the TDI. Compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a Ki = 2.1 nM and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with an IC50 = 56.9 nM. The deuterated analogue of 31 (38) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z